Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer
Authors
Harvie, M.Pegington, M.
Howell, S. J.
Bundred, N.
Foden, P.
Adams, J.
Graves, L.
Greystoke, A.
Mattson, M. P.
Cutler, R. G.
Williamson, J.
Livingstone, K.
McMullen, D.
Sellers, K.
Lombardelli, C.
Cooper, G.
McDiarmid, S.
Howell, A.
Affiliation
Prevent Breast Cancer Research Unit, The Nightingale Centre, Manchester University NHS Foundation Trust, Manchester, EnglandIssue Date
2021
Metadata
Show full item recordAbstract
Background Excess adiposity at diagnosis and weight gain during chemotherapy is associated with tumour recurrence and chemotherapy toxicity. We assessed the efficacy of intermittent energy restriction (IER) vs continuous energy restriction (CER) for weight control and toxicity reduction during chemotherapy. Methods One hundred and seventy-two women were randomised to follow IER or CER throughout adjuvant/neoadjuvant chemotherapy. Primary endpoints were weight and body fat change. Secondary endpoints included chemotherapy toxicity, cardiovascular risk markers, and correlative markers of metabolism, inflammation and oxidative stress. Results Primary analyses showed non-significant reductions in weight (−1.1 (−2.4 to +0.2) kg, p = 0.11) and body fat (−1.0 (−2.1 to +0.1) kg, p = 0.086) in IER compared with CER. Predefined secondary analyses adjusted for body water showed significantly greater reductions in weight (−1.4 (−2.5 to −0.2) kg, p = 0.024) and body fat (−1.1 (−2.1 to −0.2) kg, p = 0.046) in IER compared with CER. Incidence of grade 3/4 toxicities were comparable overall (IER 31.0 vs CER 36.5%, p = 0.45) with a trend to fewer grade 3/4 toxicities with IER (18%) vs CER (31%) during cycles 4–6 of primarily taxane therapy (p = 0.063). Conclusions IER is feasible during chemotherapy. The potential efficacy for weight control and reducing toxicity needs to be tested in future larger trials.Citation
Harvie M, Pegington M, Howell SJ, Bundred N, Foden P, Adams J, et al. Randomised controlled trial of intermittent vs continuous energy restriction during chemotherapy for early breast cancer. British Journal of Cancer.11.Journal
Br J CancerDOI
10.1038/s41416-021-01650-0PubMed ID
34912072Additional Links
https://dx.doi.org/10.1038/s41416-021-01650-0Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1038/s41416-021-01650-0
Scopus Count
Collections
Related articles
- Matched Weight Loss Through Intermittent or Continuous Energy Restriction Does Not Lead To Compensatory Increases in Appetite and Eating Behavior in a Randomized Controlled Trial in Women with Overweight and Obesity.
- Authors: Beaulieu K, Casanova N, Oustric P, Turicchi J, Gibbons C, Hopkins M, Varady K, Blundell J, Finlayson G
- Issue date: 2020 Mar 1
- Intermittent energy restriction is comparable to continuous energy restriction for cardiometabolic health in adults with central obesity: A randomized controlled trial; the Met-IER study.
- Authors: Pinto AM, Bordoli C, Buckner LP, Kim C, Kaplan PC, Del Arenal IM, Jeffcock EJ, Hall WL
- Issue date: 2020 Jun
- Intermittent v. continuous energy restriction: differential effects on postprandial glucose and lipid metabolism following matched weight loss in overweight/obese participants.
- Authors: Antoni R, Johnston KL, Collins AL, Robertson MD
- Issue date: 2018 Mar
- Could Intermittent Energy Restriction and Intermittent Fasting Reduce Rates of Cancer in Obese, Overweight, and Normal-Weight Subjects? A Summary of Evidence.
- Authors: Harvie MN, Howell T
- Issue date: 2016 Jul
- Compensatory mechanisms activated with intermittent energy restriction: A randomized control trial.
- Authors: Coutinho SR, Halset EH, Gåsbakk S, Rehfeld JF, Kulseng B, Truby H, Martins C
- Issue date: 2018 Jun